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Iron accumulation to toxic and eventually lethal levels can result from repeated blood transfusions, e.g. in β-thalassemia major and sickle cell disease, or from excessive dietary iron uptake, since humans are unable to actively eliminate iron from the body. Iron chelators slowly mobilize deposits of accumulated iron, most likely by continuously binding the small amounts of soluble iron in the "labile pool", which are in equilibrium with the insoluble hemosiderins (Crichton and Ward, 2003) . Deferasirox (Exjade ® , ICL670, Novartis Pharma AG, Basel, Switzerland) is an orally active iron chelator under development (Nick et al., 2003; Nisbet-Brown et al., 2003) and recently approved by some health authorities including the American Food and Drug Administration. Two molecules of deferasirox can form a complex with ferric iron 2, Figure 1 ) (Steinhauser et al., 2004) ; solubilized, chelated iron is then excreted.
For many years Desferal
® has been the only iron chelator approved for general use. However, its unfavorable pharmacokinetics (very short plasma half-life and poor oral bioavailability (Porter, 2001) ) necessitate special modes of application (daily subcutaneous or intravenous infusions) which are poorly accepted by many patients. This leads to a poor compliance, despite the bad prognosis of untreated iron overload. An orally active iron chelator would be expected to improve the compliance and therefore the clinical responses, will be usable also in areas with less developed infrastructure and facilitate the treatment of other diseases, including non-transfusion dependent thalassemias, anemias and possibly hemochromatosis.
The blood binding parameters of a drug can be critical for its pharmacokinetics and are needed for a comparison of pharmacokinetics across species. Here we report the blood distribution and plasma protein binding of deferasirox and its iron complex for species used in preclinical safety investigations and healthy humans, and characterize the interaction of the two molecules with human serum albumin (HSA). The employed concentrations cover the clinically and pre-clinically relevant range.
This article has not been copyedited and formatted. The final version may differ from this version. The lipoproteins were delivered as solutions in 150 mM NaCl and 0.01% EDTA, pH 7.4. The concentrations of the lipoproteins as given by the manufacturer were adjusted to the used concentrations with PBS. Human blood was taken from healthy male volunteers. Rat blood was from male albino rats (Hanover, Wistar), mouse blood from male p53 wild type mice (B6.129-Trp53 tm1Brd+ N5), dog blood from male beagles, monkey blood from male and female marmoset monkeys (Callithrix Jacchus) and rabbit blood from male or female rabbits (New Zealand White). Heparin was used as anticoagulant, all blood and plasma specimen were pooled (n ≥3, with the exception of marmoset blood which was from one male and one female animal). Fresh blood was used within 24 h (marmoset blood was slightly older due to the necessity of shipment); plasma was defrosted from storage at -20°C. In vitro interconversion between deferasirox and its iron complex was investigated in rat blood and plasma at 37°C (Novartis, non published data). Iron complex formation in plasma spiked with 4 or 80 µg/mL of deferasirox was ≤ 5 or ~ 2%, respectively, after one hour of incubation. Iron complex decay in plasma spiked with 4 or 80 µg/mL of Fe-[ICL670] 2 was about 22 or 7%, respectively, after one hour of incubation. Since both forms of deferasirox are very highly bound to plasma proteins the data on binding in plasma reported here do not contain a strong bias due to complex formation or decay. Iron complex formation in blood spiked with 4 or 80 µg/mL of deferasirox was ≤ 5 or ~ 2%, respectively, after one hour of incubation. Iron complex decay in blood spiked with 4 or 80 µg/mL of Fe-[ICL670] 2 was about 17 or 5%, respectively, after one hour of incubation. Since the blood distribution of both forms of deferasirox was similar (see Table 1 ) most of the data on blood distribution reported here do not contain a relevant bias due to complex formation or decay. Only incubations with low concentrations of [ 14 C]Fe-[ICL670] 2 might slightly underestimate f p due to some decay of the iron complex.
Control experiments.
Blood distribution. Fresh blood was spiked to the desired compound concentrations. First, kinetics of distribution were determined. In all experiments reported here incubations were for 1 h at 37°C, which was sufficient to reach an equilibrium. Sedimentation of cells was by centrifugation (1500 g, 10 min, 37°C). Radioactivity was measured in blood (C b ) before and in plasma (C p ) after centrifugation, hematocrit (H) was determined in triplicate. The fraction in plasma (f p ) was calculated as follows:
This article has not been copyedited and formatted. The final version may differ from this version. Plasma protein binding. Plasma or solutions of plasma proteins in PBS were spiked to the desired compound concentrations. All incubations were for 1 h at 37°C before centrifugation in Centrifree or Microcon (mouse and marmoset plasma and lipoprotein solutions) devices (7-10 min, 2000 g, 37°C, ~ 20% of sample filtered, shorter centrifugation times for protein solutions). Radioactivity was determined in the spiked solution (C t ) and the ultrafiltrate (C u ).
The unbound fraction (f u ) was calculated as follows: f u (%) = C u /C t x 100
IC 50 values were determined from competition data by nonlinear least-squares fitting to the four-parameter logistic function using Sigma Plot (Systat Software Inc., Richmond, CA, USA).
Results
In the investigated concentration range (4 -80 µg/mL, 11 -214 µM for deferasirox and 5. Binding to isolated human plasma proteins was measured at physiologically relevant concentrations of the major plasma proteins involved in drug binding (Table 2) . Unbound fractions determined in presence of the tested plasma proteins indicated, that both deferasirox as well as its iron complex were predominantly bound to HSA. Both deferasirox and Fe-
[ICL670] 2 were not significantly bound to hemopexin, a heme-binding plasma glycoprotein (data not shown).
In human plasma displacement of both diazepam and warfarin at high concentrations of deferasirox was found ( values of 84 µg/mL (225 µM) and 41 µg/mL (55 µM), respectively (Table 3) .
Discussion
Deferasirox as well as its iron complex were very highly bound to plasma proteins in all (Table 3) , likely due to the higher albumin concentration in the latter experiment. The observed displacement from HSA could be due to a direct competition at the binding site or an allosteric interaction.
Recent data from co-crystallization experiments indicate that phenylbutazone and indomethacin can bind simultaneously to Sudlow's Site I (Ghuman et al., 2005) . These structural data show that the size and the flexibility of this binding site should not only allow for binding of deferasirox, but also of its relatively bulky iron complex. In addition Ghuman and coworkers show that many drugs bind to albumin also at a secondary or even tertiary binding site. In case of deferasirox and its iron complex binding to several sites could explain the relatively high concentrations of the compounds necessary to displace warfarin, despite their very high binding to albumin.
Patients treated with deferasirox in clinical trials experienced high plasma concentrations of up to 250 µM deferasirox at supra therapeutic doses, concentrations of the iron complex where several fold lower (Galanello et al., 2003 ) (Nisbet-Brown et al., 2003 . Even though the binding capacity of albumin in plasma is very high due to its high concentration of about 40 mg/mL (0.6 mM) in healthy human subjects, some displacement of other HSA bound drugs can occur at such high drug concentrations. Displacement of drugs from binding sites on plasma proteins has been discussed as a mechanism of clinically relevant drug-druginteraction. However, there is a broad agreement that even though displacement can occur, the effect is usually limited to a change in the total plasma concentration of the displaced drug This article has not been copyedited and formatted. The final version may differ from this version. with an unchanged or only temporary changed exposure to unbound drug and no need for a dose adjustment (Benet and Hoener, 2002; Rolan, 1994; Sansom and Evans, 1995) . A clinical significance of displacement by deferasirox can not be completely excluded but is restricted to the very rare cases of highly protein bound drugs with a narrow therapeutic index that are either given parenterally and have a high extraction ratio or that are given orally and have a very rapid pharmacokinetic-pharmacodynamic equilibration time (Benet and Hoener, 2002; Sansom and Evans, 1995) . This article has not been copyedited and formatted. The final version may differ from this version. 
